BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28578025)

  • 1. Multimarker risk stratification approach at multiple sclerosis onset.
    Fernández-Paredes L; Casrouge A; Decalf J; de Andrés C; Villar LM; Pérez de Diego R; Alonso B; Álvarez Cermeño JC; Arroyo R; Tejera-Alhambra M; Navarro J; Oreja-Guevara C; López Trascasa M; Seyfferth A; García Martínez MA; Álvarez Lafuente R; Albert ML; Sánchez-Ramón S
    Clin Immunol; 2017 Aug; 181():43-50. PubMed ID: 28578025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma biomarkers discriminate clinical forms of multiple sclerosis.
    Tejera-Alhambra M; Casrouge A; de Andrés C; Seyfferth A; Ramos-Medina R; Alonso B; Vega J; Fernández-Paredes L; Albert ML; Sánchez-Ramón S
    PLoS One; 2015; 10(6):e0128952. PubMed ID: 26039252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
    Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
    J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry.
    Teunissen CE; Koel-Simmelink MJ; Pham TV; Knol JC; Khalil M; Trentini A; Killestein J; Nielsen J; Vrenken H; Popescu V; Dijkstra CD; Jimenez CR
    Mult Scler; 2011 Jul; 17(7):838-50. PubMed ID: 21505015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis.
    Avsar T; Korkmaz D; Tütüncü M; Demirci NO; Saip S; Kamasak M; Siva A; Turanli ET
    Mult Scler; 2012 Aug; 18(8):1081-91. PubMed ID: 22252467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human kallikrein 6 cerebrospinal levels are elevated in multiple sclerosis.
    Hebb AL; Bhan V; Wishart AD; Moore CS; Robertson GS
    Curr Drug Discov Technol; 2010 Jun; 7(2):137-40. PubMed ID: 20836755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurolymphatic biomarkers of brain endothelial inflammatory activation: Implications for multiple sclerosis diagnosis.
    Yun JW; Cvek U; Kilgore PCSR; Tsunoda I; Omura S; Sato F; Zivadinov R; Ramanathan M; Minagar A; Alexander JS
    Life Sci; 2019 Jul; 229():116-123. PubMed ID: 31082401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosis.
    Verbeek MM; Notting EA; Faas B; Claessens-Linskens R; Jongen PJ
    Acta Neurol Scand; 2010 May; 121(5):309-14. PubMed ID: 19925532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis.
    Fainardi E; Castellazzi M; Bellini T; Manfrinato MC; Baldi E; Casetta I; Paolino E; Granieri E; Dallocchio F
    Mult Scler; 2006 Jun; 12(3):294-301. PubMed ID: 16764342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases.
    Brettschneider J; Jaskowski TD; Tumani H; Abdul S; Husebye D; Seraj H; Hill HR; Fire E; Spector L; Yarden J; Dotan N; Rose JW
    J Neuroimmunol; 2009 Dec; 217(1-2):95-101. PubMed ID: 19879655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF enrichment of highly differentiated CD8+ T cells in early multiple sclerosis.
    Jilek S; Schluep M; Rossetti AO; Guignard L; Le Goff G; Pantaleo G; Du Pasquier RA
    Clin Immunol; 2007 Apr; 123(1):105-13. PubMed ID: 17188575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF Levels of CXCL12 and Osteopontin as Early Markers of Primary Progressive Multiple Sclerosis.
    Marastoni D; Magliozzi R; Bolzan A; Pisani AI; Rossi S; Crescenzo F; Montemezzi S; Pizzini FB; Calabrese M
    Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34588298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular-based diagnosis of multiple sclerosis and its progressive stage.
    Barbour C; Kosa P; Komori M; Tanigawa M; Masvekar R; Wu T; Johnson K; Douvaras P; Fossati V; Herbst R; Wang Y; Tan K; Greenwood M; Bielekova B
    Ann Neurol; 2017 Nov; 82(5):795-812. PubMed ID: 29059494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple sclerosis and optic neuritis: CCR5 and CXCR3 expressing T cells are augmented in blood and cerebrospinal fluid.
    Teleshova N; Pashenkov M; Huang YM; Söderström M; Kivisäkk P; Kostulas V; Haglund M; Link H
    J Neurol; 2002 Jun; 249(6):723-9. PubMed ID: 12111306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease.
    Scarpini E; Galimberti D; Baron P; Clerici R; Ronzoni M; Conti G; Scarlato G
    J Neurol Sci; 2002 Mar; 195(1):41-6. PubMed ID: 11867072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis.
    Komori M; Blake A; Greenwood M; Lin YC; Kosa P; Ghazali D; Winokur P; Natrajan M; Wuest SC; Romm E; Panackal AA; Williamson PR; Wu T; Bielekova B
    Ann Neurol; 2015 Jul; 78(1):3-20. PubMed ID: 25808056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chitinase effects on immune cell response in neuromyelitis optica and multiple sclerosis.
    Correale J; Fiol M
    Mult Scler; 2011 May; 17(5):521-31. PubMed ID: 21159721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor-alfa and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis.
    Obradović D; Kataranovski M; Dincić E; Obradović S; Colić M
    Vojnosanit Pregl; 2012 Feb; 69(2):151-6. PubMed ID: 22500369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum and cerebrospinal fluid nitrite and nitrate levels in relapsing-remitting and secondary progressive multiple sclerosis patients.
    Yuceyar N; Taşkiran D; Sağduyu A
    Clin Neurol Neurosurg; 2001 Dec; 103(4):206-11. PubMed ID: 11714562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Albumin and Protein Oxidation are Predictors that Differentiate Relapsing-Remitting from Progressive Clinical Forms of Multiple Sclerosis.
    Oliveira SR; Kallaur AP; Reiche EMV; Kaimen-Maciel DR; Panis C; Lozovoy MAB; Morimoto HK; Maes M; Dichi I; Simão ANC
    Mol Neurobiol; 2017 May; 54(4):2961-2968. PubMed ID: 27026183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.